Literature DB >> 6148960

Effects of xamoterol (ICI 118,587) in asthmatic patients.

C G Löfdahl, N Svedmyr.   

Abstract

To study the cardioselectivity of xamoterol, eight asthmatic patients took part in a randomised, double-blind, cross-over study, in which xamoterol or saline were infused, followed by four increasing doses of terbutaline i.v. Circulatory studies showed a significant increase of systolic blood pressure after xamoterol 0.1 mg/kg compared to saline (P less than 0.05), and heart rate tended to increase. Diastolic blood pressure did not show any significant changes after the different treatments. Skeletal muscle tremor measurements with terbutaline stimulation did not show any differences after pre-treatment with either xamoterol or saline. Mean values of FEV1 did not reveal any significant difference before or after terbutaline stimulation between xamoterol and saline pre-treatments. However, in one patient, FEV decreased 60% after xamoterol, an effect which was reversed by terbutaline. Xamoterol did not have any effect on beta-adrenoceptor mediated skeletal muscle tremor and no significant effect on beta-adrenoceptor mediated bronchodilation in doses which gave a significant increase of systolic blood pressure. Thus, xamoterol was shown to be a selective beta 1-adrenoceptor agonist in man.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6148960      PMCID: PMC1463625          DOI: 10.1111/j.1365-2125.1984.tb02510.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  6 in total

1.  Evaluation of skeletal muscle tremor due to bronchodilator agents.

Authors:  G Thiringer; N Svedmyr
Journal:  Scand J Respir Dis       Date:  1975-08

2.  Selectivity of beta-adrenoceptor agonists and antagonists in asthmatics.

Authors:  C G Löfdahl
Journal:  Eur J Respir Dis Suppl       Date:  1982

3.  Pafenolol, a highly selective beta 1-adrenoceptor-antagonist, in asthmatic patients: interaction with terbutaline.

Authors:  C G Löfdahl; G E Marlin; N Svedmyr
Journal:  Clin Pharmacol Ther       Date:  1983-01       Impact factor: 6.875

4.  Effect of prenalterol in asthmatic patients.

Authors:  C G Löfdahl; N Svedmyr
Journal:  Eur J Clin Pharmacol       Date:  1982-10       Impact factor: 2.953

5.  The cardiovascular effects of ICI 118,587: A beta 1-adrenoceptor partial agonist.

Authors:  A Nuttall; H M Snow
Journal:  Br J Pharmacol       Date:  1982-10       Impact factor: 8.739

6.  Effects of a cardioselective beta 1 partial agonist (corwin) on left ventricular function and myocardial metabolism in patients with previous myocardial infarction.

Authors:  M F Rousseau; H Pouleur; M F Vincent
Journal:  Am J Cardiol       Date:  1983-05-01       Impact factor: 2.778

  6 in total
  11 in total

1.  Is xamoterol safe in chronic airflow obstruction?

Authors:  J A Roberts; V F Challenor; D G Waller
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 2.  Beta-adrenoceptor partial agonists: a renaissance in cardiovascular therapy?

Authors:  D G Waller
Journal:  Br J Clin Pharmacol       Date:  1990-08       Impact factor: 4.335

Review 3.  Xamoterol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.

Authors:  R Furlong; R N Brogden
Journal:  Drugs       Date:  1988-10       Impact factor: 9.546

4.  Modulation of the autonomic control of the failing heart.

Authors:  H M Snow
Journal:  Basic Res Cardiol       Date:  1989       Impact factor: 17.165

Review 5.  The pharmacology of xamoterol: a basis for modulation of the autonomic control of the heart.

Authors:  H M Snow
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

6.  Myocardial, coronary, and peripheral effects of xamoterol (ICI 118,587) in open-chest pigs.

Authors:  N Galiè; M Metalli; R Zannoli; G Binetti; A Branzi; B Magnani
Journal:  Cardiovasc Drugs Ther       Date:  1989-03       Impact factor: 3.727

Review 7.  Long-term studies with xamoterol in heart failure.

Authors:  D G Waller
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

8.  Ketotifen and cardiovascular effects of xamoterol following single and chronic dosing in healthy volunteers.

Authors:  R F Schäfers; I Karl; K Mennicke; A E Daul; T Philipp; O E Brodde
Journal:  Br J Clin Pharmacol       Date:  1999-01       Impact factor: 4.335

9.  Effects of rolipram and siguazodan on the human isolated bronchus and their interaction with isoprenaline and sodium nitroprusside.

Authors:  Y Qian; E Naline; J A Karlsson; D Raeburn; C Advenier
Journal:  Br J Pharmacol       Date:  1993-07       Impact factor: 8.739

10.  Differential effects of beta-adrenoceptor partial agonists in patients with postural hypotension.

Authors:  J Mehlsen; C Stadeager; J Trap-Jensen
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.